Thymosin α1 Acetate

Product Name Thymosin α1 Acetate

Sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-

Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-

Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH

Cas No. 62304-98-7

Molecular Formula C129H215N33O55

Molecular Weight 3108.3

Purity (HPLC) 98.0%min.

Appearance? White powder

Single Impurity (HPLC)? 1.0%max

Amino Acid Composition? ±10% of theoretical

Peptide Content (N%) ?≥80.0%

Water Content(Karl Fischer)? ≤5.0%

Specific Rotation (20/D) -95.0～-105.0°(c=0.5 1%HAc)

Description:

Thymosin Alpha-1 is a component of Thymosin Fraction 5 responsible for restoring immune function in animals lacking thymus glands. It was the original peptide synthesized from the Thymosin Fraction 5. Unlike β Thymosins, which are genetically and chemically unrelated, Thymosin α 1 is produced as a 28-amino acid peptide fragment from a longer, 113-amino acid precursor, prothymosin alpha. Research has shown it to enhance cell-mediated immunity in experimental animals and research subjects...

Thymosin Alpha-1 is being researched for the treatment of Hepatitis B and C, and it is also approved for inclusion with vaccines to boost the immune response in the treatment of other diseases.

Exhibiting a variety of immune regulating properties, thymosin-alpha-1 induces differentiation of murine T-cell precursors and human thymocytes and the terminal differentiation of functionally immature cord blood lymphocytes and induces production of IL-2, high affinity IL-2 receptors, and B-cell growth factors by peripheral blood mononuclear cells. T-helper and cytotoxic/suppressor T-cell populations are targets of thymosin activity. Thymosin-alpha-1 has been shown to increase the efficiency of antigen presentation by macrophages and to be an endogenous modulator of alpha-thrombin activity.

Application:

Thymosin α 1 is now approved in 35 under developed or developing countries for the treatment of Hepatitis B and C, and it is also used to boost the immune response in the treatment of other diseases.